NASDAQ NMS - GLOBAL MARKET · BCAX
-0.80% · -$0.2100 · Vol 818.3K
After hours · updated 16:51:28 ET
Bicara Therapeutics Inc

Bicara Therapeutics Inc

Biotechnology
$25.89
Card
Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factorsMethodology
BCAX
Bicara Therapeutics Inc
Stale score · Tue Aug 4 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

65/ 100
Veridion Score
BUY BIAS · HIGH confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Stale score · Tue Aug 4 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Score not reportedVeridion does not publish a score-history trend for BCAX until the ticker has a real scored snapshot. No trend is implied for this page.Review methodology
AI Analysis
Sovereign

Why is BCAX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading BCAX catalysts
About Bicara Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2024
Employees
103
Country
US

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$26.31
Day high
$26.62
Day low
$25.34
Previous close
$26.10
52W high
$26.62
-2.74% from high
52W low
$25.34
43% of range
Market cap
$1.7B
Shares out
65.7M
Volume
818.3K
VWAP
$25.84
Price history computed in-house
SMA 50 Not reported · Not reported
SMA 200 Not reported · Not reported
52W position 43%

BCAX overview

Veridion Score
Not reported
6 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around BCAX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading BCAX Form 4 filings
Public disclosures

Congress activity in BCAX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for BCAX in the cached public ledger.

Federal contracts

BCAX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for BCAX in this window.
Lobbying spend

BCAX lobbying filings, year to date.

Registered lobbying filings matched to Bicara Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for BCAX in this window.
Loading news for BCAX
Analyst ratings
Sovereign unlock shows live analyst consensus for BCAX.
Options
Sovereign unlock shows live options positioning for BCAX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.